<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00194688</url>
  </required_header>
  <id_info>
    <org_study_id>01-8470-V 04</org_study_id>
    <secondary_id>2R44DK055935-02</secondary_id>
    <nct_id>NCT00194688</nct_id>
  </id_info>
  <brief_title>Breath Ammonia Method for H. Pylori Detection: Phase II</brief_title>
  <official_title>Breath Ammonia Method for H. Pylori Detection: Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <brief_summary>
    <textblock>
      The objective is to evaluate the utility of a breath ammonia sensing device. In this study we&#xD;
      will assess the effect of H. pylori infection on breath ammonia levels by measuring whether&#xD;
      there is a change in the pattern or quantity of breath ammonia seen in H. pylori positive&#xD;
      patients compared to H. pylori negative patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers will undergo testing for H. pylori infection using a 14-C urea breath&#xD;
      test, and the results will be compared to an experimental ammonia breath test. The breath&#xD;
      sample will be collected by an investigational device that the patient will be exposed to&#xD;
      consisting of a plastic mouth-piece which is attached to a T-tubing section having a side-arm&#xD;
      port through which a fiberoptic ammonia sensor is inserted inside the tube. To meet the Phase&#xD;
      II specific aim, the scope of the clinical trials is expanded addressing the following&#xD;
      specific objectives:&#xD;
&#xD;
        -  Test refinements of the sensing system (hardware, software, &amp; breath test device)&#xD;
&#xD;
        -  Determine whether a urea dose-response effect exists following urea ingestion,&#xD;
&#xD;
        -  Define the optimal cutoff values for expired breath ammonia to allow optimal&#xD;
           discrimination of H. pylori infected vs. uninfected persons.&#xD;
&#xD;
        -  Determine the appropriate time interval for breath ammonia testing following urea&#xD;
           ingestion.&#xD;
&#xD;
        -  Determine whether there is a change in breath ammonia level after H. pylori treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date>June 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of breath ammonia measurement for H. pylori infection</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of a dose response relationship for oral urea dose and breath ammonia level.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of whether breath ammonia measurement allows determination of successful H. pylori treatment.</measure>
  </secondary_outcome>
  <enrollment>278</enrollment>
  <condition>Helicobacter Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H. pylori treatment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult volunteers not meeting exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known cirrhosis of the liver&#xD;
&#xD;
          -  Renal insufficiency (BUN greater than 40 mg/dl, Creatinine greater than 2.0 mg/dl).&#xD;
&#xD;
          -  Prior gastric resection&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (Forced expiratory volume in 1 second&#xD;
             less than 1.5 L)&#xD;
&#xD;
          -  Patients unwilling or unable to discontinue proton pump inhibitors for 2 weeks prior&#xD;
             to scheduled 14C or non-isotopic urea breath testing&#xD;
&#xD;
          -  Patients who have received antibiotics or bismuth within the preceding month.&#xD;
&#xD;
          -  Patients unwilling or unable to give informed consent&#xD;
&#xD;
          -  Pregnant women (14C urea breath test is not approved for use in pregnant women)&#xD;
&#xD;
          -  Age less than 21 years (14C urea breath test is not approved for use in children)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David L Putnam, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pacific Technologies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>January 2, 2008</last_update_submitted>
  <last_update_submitted_qc>January 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>David Kearney, MD</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>ammonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

